Estrella Immunopharma, Inc. (ESLA) Balance Sheet
ESLA balance sheet, 2025
December 31, 2025 · U.S. dollars$3.2M assets = $13.5M liabilities + −$10.4M equity
Liabilities exceed assets: shareholders’ equity is negative (−$10.4M).
Both columns are drawn to the same scale: what ESLA owns equals what it owes plus shareholders’ equity. Hover a block for its value.
ESLA financial health
Descriptive bands, not a rating. Fiscal 2025.
ESLA balance sheet trends, 2020–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $02020 | $3.2M2025 | — | |
| Total liabilities | $02020 | $13.5M2025 | — | |
| Shareholders’ equity | $02020 | −$10.4M2025 | — | |
| Cash & short-term investments | $02020 | $1.4M2025 | — | |
| Working capital | $02020 | −$11.9M2025 | −$11.9M | |
| Book value per share | $0.002020 | −$0.282025 | — | |
| Current ratio | 5.202021 | 0.122025 | −5.08 | |
| Shares outstanding | 35.2M2020 | 36.8M2025 | +0.9%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
ESLA assets
ESLA liabilities and equity
ESLA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
ESLA balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Cash & short-term investments | $1.4M | $916,916 | $4.2M | $40,802 | $4.1M | $0 |
| Cash & equivalents | $1.4M | $916,916 | $4.2M | $40,802 | $4.1M | $0 |
| Receivables | $0 | $288,761 | $0 | $273,066 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $292,673 | $435,100 | $288,761 | $0 | $833,333 | $0 |
| Total current assets | $1.7M | $1.6M | $4.5M | $52,427 | $4.9M | $0 |
| Property, plant & equipment (net) | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $1.5M | $1.5M | $0 | $9.9M | $0 | $0 |
| Total assets | $3.2M | $3.1M | $4.5M | $10.0M | $4.9M | $0 |
| Liabilities | ||||||
| Accounts payable | $554,781 | $77,076 | $0 | $46,879 | $945,587 | $0 |
| Short-term debt | — | — | — | $498,600 | — | — |
| Total current liabilities | $13.5M | $3.0M | $180,701 | $1.1M | $946,684 | $0 |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 |
| Other long-term liabilities | $0 | $0 | $0 | $1.8M | $5.0M | $0 |
| Total liabilities | $13.5M | $3.0M | $180,701 | $2.9M | $6.0M | $0 |
| Shareholders' equity | ||||||
| Common stock & paid-in capital | $3,849 | $3,668 | — | $98 | $18 | — |
| Retained earnings (deficit) | −$37.0M | −$23.9M | −$19.5M | −$2.3M | −$1.1M | $0 |
| Total shareholders' equity | −$10.4M | $143,731 | $4.3M | $7.1M | −$1.0M | $0 |
| Key figures | ||||||
| Total debt | — | — | — | $498,600 | — | — |
| Net cash (debt) | — | — | — | −$457,798 | — | — |
| Working capital | −$11.9M | −$1.4M | $4.3M | −$1.0M | $4.0M | $0 |
| Tangible book value | −$10.4M | $143,731 | $4.3M | $7.1M | −$1.0M | $0 |
| Book value per share | −$0.28 | $0.00 | $0.12 | $0.20 | −$0.03 | $0.00 |
| Shares outstanding | 36.8M | 36.7M | 36.3M | 35.2M | 35.2M | 35.2M |
| Current ratio | 0.12 | 0.55 | 24.65 | 0.05 | 5.20 | — |
| Quick ratio | 0.10 | 0.40 | 23.05 | 0.29 | 4.32 | — |
| Debt / equity | — | — | — | 0.07 | — | — |
| Equity / assets | −326.3% | 4.6% | 95.9% | 70.8% | −21.1% | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $146,670 | $1.9M | $1.4M | $1.6M | $1.3M | $421,473 | $916,916 | $1.8M | $4.2M | $4.7M | $9.0M | $22.1M |
| Cash & equivalents | $146,670 | $1.9M | $1.4M | $1.6M | $1.3M | $421,473 | $916,916 | $1.8M | $4.2M | $4.7M | $9.0M | $22.1M |
| Receivables | $0 | $229,794 | $0 | $396,901 | $163,933 | $522,795 | $0 | $437,642 | $288,761 | $406,110 | $288,761 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | −$288,760 | −$288,760 | −$406,110 | −$406,110 | $0 |
| Other current assets | $1.7M | $0 | $292,673 | $0 | $0 | $0 | $723,861 | $288,760 | $288,760 | $3.9M | $0 | $5.2M |
| Total current assets | $1.8M | $2.2M | $1.7M | $2.0M | $1.5M | $944,268 | $1.6M | $2.2M | $4.5M | $8.6M | $4.5M | $27.3M |
| Property, plant & equipment (net) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $1.5M | $1.5M | $1.5M | $1.5M | $1.5M | $1.5M | $1.5M | $0 | $0 | $5.0M | $0 |
| Total assets | $1.8M | $3.7M | $3.2M | $3.5M | $3.0M | $2.4M | $3.1M | $3.7M | $4.5M | $8.6M | $9.4M | $27.3M |
| Liabilities | ||||||||||||
| Accounts payable | $8,232 | $14,947 | $554,781 | $5,631 | $8,154 | $13,988 | — | $5,000 | $0 | $0 | $77,076 | $9.3M |
| Short-term debt | — | — | — | $4,000 | $4,000 | $10,000 | — | $4,000 | $6,000 | — | — | $300,000 |
| Total current liabilities | $9.3M | $8.9M | $13.5M | $13.4M | $9.1M | $4.3M | $3.0M | $3.0M | $180,701 | $138,491 | $398,733 | $17.3M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other long-term liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total liabilities | $9.3M | $8.9M | $13.5M | $13.4M | $9.1M | $4.3M | $3.0M | $3.0M | $180,701 | $138,491 | $398,733 | $17.3M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $4,355 | $4,318 | $3,849 | $3,828 | $3,758 | $3,668 | $3,668 | $3,661 | $3,661 | $3,661 | $3,661 | $3,520 |
| Retained earnings (deficit) | −$41.6M | −$39.3M | −$37.0M | −$36.4M | −$31.6M | −$26.0M | −$23.9M | −$22.9M | −$19.5M | −$15.5M | −$19.5M | −$14.1M |
| Accumulated other comprehensive income | — | — | — | — | — | — | — | −$4.5M | — | — | — | — |
| Total shareholders' equity | −$7.4M | −$5.3M | −$10.4M | −$9.8M | −$6.1M | −$1.8M | $143,731 | $746,286 | $4.3M | $8.5M | $9.0M | $10.1M |
| Key figures | ||||||||||||
| Total debt | — | — | — | $4,000 | $4,000 | $10,000 | — | $4,000 | $6,000 | — | — | $300,000 |
| Net cash (debt) | — | — | — | $1.6M | $1.3M | $411,473 | — | $1.8M | $4.2M | — | — | $21.8M |
| Working capital | −$7.4M | −$6.8M | −$11.9M | −$11.3M | −$7.6M | −$3.3M | −$1.4M | −$753,714 | $4.3M | $8.5M | $4.1M | $10.1M |
| Tangible book value | −$7.4M | −$5.3M | −$10.4M | −$9.8M | −$6.1M | −$1.8M | $143,731 | $746,286 | $4.3M | $8.5M | $9.0M | $10.1M |
| Book value per share | −$0.17 | −$0.13 | −$0.27 | −$0.27 | −$0.17 | −$0.05 | $0.00 | $0.02 | $0.12 | $0.24 | $0.26 | $0.29 |
| Shares outstanding | 43.0M | 42.1M | 38.0M | 37.1M | 36.2M | 36.2M | 36.7M | 36.2M | 36.6M | 35.5M | 35.2M | 35.2M |
| Current ratio | 0.20 | 0.24 | 0.12 | 0.15 | 0.16 | 0.22 | 0.55 | 0.75 | 24.65 | 62.34 | 11.17 | 1.58 |
| Quick ratio | 0.02 | 0.24 | 0.10 | 0.15 | 0.16 | 0.22 | 0.31 | 0.75 | 24.65 | 37.07 | 23.41 | 1.28 |
| Debt / equity | — | — | — | — | — | — | — | 0.01 | 0.00 | — | — | 0.03 |
| Equity / assets | −407.3% | −144.1% | −326.3% | −279.2% | −204.5% | −74.9% | 4.6% | 20.0% | 95.9% | 98.4% | 95.8% | 36.8% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 18, 2026); data from EODHD.
ESLA financial position
At the end of fiscal 2025 (December 31, 2025), Estrella Immunopharma had total assets of $3.2 million (up 1.2% from a year earlier), total liabilities of $13.5 million and shareholders' equity of -$10.4 million. Its current ratio was 0.12. In the latest quarter (ended June 30, 2026) total assets were $1.8 million and equity -$7.4 million.
Related: ESLA income statement, ESLA cash flow statement, ESLA key metrics. See the ESLA stock overview for the latest quote and news.
ESLA balance sheet FAQ
What are Estrella Immunopharma's total assets?
Estrella Immunopharma reported total assets of $3.2 million at the end of fiscal 2025 (December 31, 2025), compared with $3.1 million a year earlier.
How much cash does Estrella Immunopharma have?
Estrella Immunopharma held $1.4 million in cash and short-term investments at the end of fiscal 2025.
What is Estrella Immunopharma's book value?
Estrella Immunopharma's shareholders' equity (book value) was -$10.4 million at the end of fiscal 2025, or −$0.28 per share.
What is Estrella Immunopharma's current ratio?
Estrella Immunopharma had current assets of $1.7 million and current liabilities of $13.5 million, a current ratio of 0.12 (current liabilities exceed current assets).